THE PLACE OF COMBINATION THERAPY IN THE TREATMENT OF HYPERTENSION IN 1993

被引:45
作者
CHALMERS, J
机构
[1] Department of Medicine, Flinders Medical Centre, Adelaide
关键词
DRUG COMBINATIONS; DIURETICS; BETA-BLOCKERS; ALPHA-BLOCKERS; CALCIUM ANTAGONISTS; ACE INHIBITORS; ESSENTIAL HYPERTENSION; SYSTOLIC HYPERTENSION;
D O I
10.3109/10641969309037113
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
''Step Care'' fell into disuse following the advent of the ACE inhibitors and calcium antagonists. This was partly because the potency of these agents encouraged their use in monotherapy, and partly because of dissatisfaction with ritual treatment using multiple drugs. However monotherapy too has its problems, not the least of which is ritual increase in the dose of the first drug prescribed, leading to prolonged treatment with high doses and hence an increase in side effects. It is therefore important to consider changing to an alternative drug rather than automatically increasing the dose, or adding a second drug. Combination therapy still has a major place in the treatment of hypertension. It is necessary in patients with severe hypertension, with clinical manisfestations of target organ damage, or with associated conditions that often help the doctor to choose a rational combination. Even in patients with uncomplicated mild hypertension, the achievement of goal blood pressure requires combination therapy in around half the cases. By choosing two drugs from appropriate classes of agent, it is possible to add the primary actions of drugs acting through different mechanisms, while opposing the homeostatic compensations that limit the fall in blood pressure. Effective combinations therefore maximise hypotensive efficacy while minimising side effects. Effective combinations for the treatment of classical and of systolic hypertension, are discussed.
引用
收藏
页码:1299 / 1313
页数:15
相关论文
共 33 条
[1]  
AMERY A, 1985, LANCET, V1, P1349
[2]  
[Anonymous], 1991, JAMA, V265, P3255
[3]  
[Anonymous], 1980, LANCET, V1, P1261
[4]   INFLUENCE OF THE ANGIOTENSIN CONVERTING ENZYME-INHIBITOR CILAZAPRIL, THE BETA-BLOCKER PROPRANOLOL AND THEIR COMBINATION ON HEMODYNAMICS IN HYPERTENSION [J].
BELZ, GG ;
BREITHAUPT, K ;
ERB, K ;
KLEINBLOESEM, CH ;
WOLF, GK .
JOURNAL OF HYPERTENSION, 1989, 7 (10) :817-824
[5]  
BRUNNER HR, 1990, J HYPERTENS, V8, P3, DOI 10.1097/00004872-199001000-00002
[6]  
CAPPUCCIO FP, 1991, J HUM HYPERTENS, V5, P9
[7]  
CAPPUCCIO FP, 1991, J HUMAN HYPERTENS, V8, P144
[8]   EFFECTS OF ENALAPRIL AND HYDROCHLOROTHIAZIDE ON BLOOD-PRESSURE, RENIN-ANGIOTENSIN SYSTEM, AND ATRIAL-NATRIURETIC-FACTOR IN ESSENTIAL-HYPERTENSION - A DOUBLE-BLIND FACTORIAL CROSSOVER STUDY [J].
CHALMERS, JP ;
WING, LMH ;
WEST, MJ ;
BUNE, AJC ;
ELLIOTT, JM ;
MORRIS, MJ ;
CAIN, MD ;
GRAHAM, JR ;
SOUTHGATE, DO .
AUSTRALIAN AND NEW ZEALAND JOURNAL OF MEDICINE, 1986, 16 (04) :475-480
[9]   RANDOMIZED TRIAL OF TREATMENT OF HYPERTENSION IN ELDERLY PATIENTS IN PRIMARY CARE [J].
COOPE, J ;
WARRENDER, TS .
BRITISH MEDICAL JOURNAL, 1986, 293 (6555) :1145-1151
[10]   MORBIDITY AND MORTALITY IN THE SWEDISH TRIAL IN OLD PATIENTS WITH HYPERTENSION (STOP-HYPERTENSION) [J].
DAHLOF, B ;
LINDHOLM, LH ;
HANSSON, L ;
SCHERSTEN, B ;
EKBOM, T ;
WESTER, PO .
LANCET, 1991, 338 (8778) :1281-1285